Business
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer
About this update from Iovance Biotherapeutics, Inc.
[{"type":"text","content":"TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer 21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts with clinical data for Iovance tumor-infiltrating lymphocyte (TIL) therapy in combination with pembrolizumab in patients with advanced cancers and for Iovance TIL cell therapy in relapsed, refractory lung cancer. Additional updates will be provided at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 12-14, 2021 in Washington, D.C. and virtually. Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, “Our latest clinical data in the SITC abstracts further support the power of our TIL platform and our ongoing TIL development across multiple solid-tumor cancers and various treatment settings. We look forward to highlighting clinical data that suggest TIL in combination with pembrolizumab may increase response rates as an early line treatment for advanced cervical cancer, melanoma, and head and neck cancer. SITC will also be our first medical meeting to present clinical results for Iovance TIL in heavily pre-treated patients with metastatic non-small cell lung cancer.” Lifileucel in Combination with Pembrolizumab in Advanced CancersEarly-line treatment with single-agent pembrolizumab achieved an overall response rate (ORR) of 33% in patients with advanced melanoma¹ and 17% in patients with head and neck squamous cell carcinoma (HNSCC).² Novel early-line combination therapies are needed to improve rate and depth of responses with manageable long-term safety. Clinical data in the SITC abstract show encouraging response rates after lifileucel plus pembrolizumab in patients with immune checkpoint inhibitor (ICI)-naïve advanced melanoma and HNSCC from the IOV-COM-202 study as well as patients from the C-145-04 clinical study who were ICI- and chemotherapy-naive. The ORR in all cohorts was assessed by investigator using RECIST 1.1 and listed in the abstract as follows ...